Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects

Clinical Drug Investigation

Volumn 32, Issue 8, 2012, Pages 533-538

  Vlase, Laurian ^a   Popa, Adina ^a   Neag, Maria ^a   Muntean, Dana ^a   Leucuta, Sorin E ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

ivabradine; pharmacokinetics; phenytoin

Indexed keywords

IVABRADINE; PHENYTOIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; ANTICONVULSANTS; AREA UNDER CURVE; BENZAZEPINES; CHROMATOGRAPHY, LIQUID; HALF-LIFE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PHENYTOIN; REFERENCE VALUES; YOUNG ADULT;

EID: 84863586804     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11634450-000000000-00000     Document Type: Article

References (19)

1. Liang M, Puri A, Devlin G. Heart rate and cardiovascular disease: An alternative to beta blockers. Cardiol Res Pract 2009; 2009: 179350
2. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I-f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: A 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30: 540-548
3. Khawaja MZ, Walker DM. Ivabradine: The beauty of a slow heart rate. Int J Clin Pract 2009; 63: 542-546
4. Prasad UK, Gray D, Purcell H. Review of the I-f selective channel inhibitor ivabradine in the treatment of chronic stable angina. Adv Ther 2009; 26: 127-137
5. Milliez P, Messaoudi S, Nehme J, et al. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol-Heart C 2009; 296: h435-41
6. Riccioni G, Vitulano N, D'Orazio N. Ivabradine: Beyond heart rate control. Adv Ther 2009; 26: 12-24
7. Portoles A, Calvo A, Terleira A, et al. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: An open-label, randomized, crossover, pharmacokinetic interaction clinical trial. J Clin Pharmacol 2006; 46: 1195-1203 (Pubitemid 44387420)
8. Portoles A, Terleira A, Calvo A. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: An open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol 2006; 46: 1188-1194 (Pubitemid 44387419)
9. Vlase L, Neag M, Popa A, et al. Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. J Clin Pharm Ther 2011; 36: 225-229
10. Vlase L, Muntean D, Popa A, et al. Pharmacokinetic interaction between ivabradine and ciprofloxacin in healthy volunteers. Studia UBB Chemia 2009; 54: 265-271
11. Vlase L, Popa A, Neag M, et al. Pharmacokinetic interaction study between ivabradine with fluoxetine or metronidazole in healthy volunteers. Farmacia 2010; 58: 471-477
12. Patsalos PN, Fröscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-385 (Pubitemid 34297175)
13. Johannessen SI, Landmark CJ. Antiepileptic drug interactions: Principles and clinical implications. Curr Neuropharmacol 2010; 8 (3): 254-267
14. Chhun S, Verstuyft C, Rizzo-Padoin N, et al. Gefitinibphenytoin interaction is not correlated with the Cerythromycin breath test in healthy male volunteers. Br J Clin Pharmacol 2009; 68: 226-237
15. Vlase L, Muntean D, Leucuta SE, et al. High-throughput determination of ivabradine from human plasma by LC/MS/MS and its application to pharmacokinetic studies. Studia UBB Chemia 2009; 54: 43-52
16. Schuirmann DJ. A comparison of the 2 one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680
17. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Bioavailability and bioequivalence studies for orally administrated drug products: General considerations. Rockville (MD), 2003 [online]. Available from URL: Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Gui dances/ucm070124.pdf [Accessed 2012 Jan 11]
18. The European Agency for the Evaluation ofMedicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence. London, 2001 (CPMP/EWP/QWP/1401/98) [online]. Available from: Http://www. ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/ WC500003519.pdf [Accessed 2012 Jan 11]
19. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Drug interaction studies: Study design, data analysis, and implications for dosing and labeling. Rockville (MD), 2006 [online]. Available from URL: Http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm072101. pdf] [Accessed 2012 Jan 11]